CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 ...

PD-1, VEGFA, and CTLA-4 are clinically validated targets for immunotherapies, which can exert complementary, multi-dimensional anti-tumor effects through synergistic mechanisms. Blockade of PD-1 ...

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination ...

Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients ...

Recent studies have shown that Fc-enhanced PD-1/CTLA-4 antibodies can have an impact in microsatellite stable CRC. Other work has evaluated new combinatorial pathways with classic PD-1 blockade to ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on REPL stock prospects.

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...